Cosmos Health stock gains 14.79 percent after record revenue

Cosmos Health stock gained 14.79 percent to USD 0.41 on Nasdaq on September 23, 2026, while Q2 revenue reached USD 18.99 million. The latest corporate update points to a wider operating scale, but the stock remains 68.94 percent below its 52-week high of USD 1.32.

Revenue growth reaches 28.8 percent

Q2 2026 revenue rose 28.8 percent year over year to USD 18.99 million, according to Globenewswire in a September 3, 2026 corporate update. That comparison gives the recent price move a clear operating reference rather than leaving it as a standalone trading statistic.

H1 2026 revenue totaled USD 36.91 million, an increase of 29.7 percent from the prior-year period, the same update reported. Adjusted gross profit increased 58 percent year over year in Q2 2026, while the annualized adjusted run-rate exceeded USD 75 million.

Guidance sets a higher hurdle

Cosmos Health reaffirmed 2026 revenue guidance of more than USD 90 million on September 3, 2026, according to StockTitan. Against USD 36.91 million in first-half revenue, that target requires USD 53.09 million in the second half.

The corporate update also set a 2029 revenue target of USD 200.6 million and described a 32 percent revenue compound annual growth rate from fiscal year 2025. For investors, the central issue is whether the reported growth can translate into a more durable earnings profile as proprietary products and contract manufacturing expand.

Stock stays below its yearly high

The latest USD 0.41 Nasdaq quote on September 23, 2026 came with a market capitalization of USD 22.13 million and volume of 13,189,752 shares. The 52-week range was USD 0.16 to USD 1.32, placing the quote 68.94 percent below the upper end.

The market snapshot therefore combines a sharp one-session gain with a wide valuation distance from the yearly high. The next test is execution against the USD 90 million 2026 revenue target, not the single-day percentage alone.